Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.46−0.03 (-0.11%)
Close on Nov 18, 2026Market cap $4.54BP/E –Yield –
Adaptive Biotechnologies revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Adaptive Biotechnologies's revenue for the twelve months ending Jun 30, 2026 was $308.08M, up 50.1% year over year. For fiscal 2025 it was $276.98M, up 54.8% from the year before. The highest annual figure on record is $276.98M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.98M | +54.8% |
| FY2024 | Dec 31, 2024 | $178.96M | +5.1% |
| FY2023 | Dec 31, 2023 | $170.28M | -8.1% |
| FY2022 | Dec 31, 2022 | $185.31M | +20.1% |
| FY2021 | Dec 31, 2021 | $154.34M | +56.9% |
| FY2020 | Dec 31, 2020 | $98.38M | +15.6% |
| FY2019 | Dec 31, 2019 | $85.07M | +52.8% |
| FY2018 | Dec 31, 2018 | $55.66M | +44.8% |
| FY2017 | Dec 31, 2017 | $38.45M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $71.55M | +21.5% |
| Q1 FY2026 | Mar 31, 2026 | $70.87M | +35.1% |
| Q4 FY2025 | Dec 31, 2025 | $71.68M | +51.0% |
| Q3 FY2025 | Sep 30, 2025 | $93.97M | +102.4% |
| Q2 FY2025 | Jun 30, 2025 | $58.88M | +36.3% |
| Q1 FY2025 | Mar 31, 2025 | $52.44M | +25.2% |
| Q4 FY2024 | Dec 31, 2024 | $47.46M | +3.7% |
| Q3 FY2024 | Sep 30, 2024 | $46.44M | +22.5% |
| Q2 FY2024 | Jun 30, 2024 | $43.19M | -11.7% |
| Q1 FY2024 | Mar 31, 2024 | $41.87M | +11.2% |
| Q4 FY2023 | Dec 31, 2023 | $45.78M | -17.1% |
| Q3 FY2023 | Sep 30, 2023 | $37.92M | -20.7% |
| Q2 FY2023 | Jun 30, 2023 | $48.93M | +12.1% |
| Q1 FY2023 | Mar 31, 2023 | $37.65M | -2.5% |
| Q4 FY2022 | Dec 31, 2022 | $55.20M | +45.5% |
| Q3 FY2022 | Sep 30, 2022 | $47.83M | +21.2% |
| Q2 FY2022 | Jun 30, 2022 | $43.66M | +13.4% |
| Q1 FY2022 | Mar 31, 2022 | $38.62M | +0.5% |
| Q4 FY2021 | Dec 31, 2021 | $37.93M | +25.7% |
| Q3 FY2021 | Sep 30, 2021 | $39.47M | +50.1% |
| Q2 FY2021 | Jun 30, 2021 | $38.51M | +83.5% |
| Q1 FY2021 | Mar 31, 2021 | $38.44M | +83.8% |
| Q4 FY2020 | Dec 31, 2020 | $30.19M | +24.7% |
| Q3 FY2020 | Sep 30, 2020 | $26.30M | +0.9% |
| Q2 FY2020 | Jun 30, 2020 | $20.99M | -5.2% |
| Q1 FY2020 | Mar 31, 2020 | $20.91M | +65.1% |
| Q4 FY2019 | Dec 31, 2019 | $24.21M | +40.8% |
| Q3 FY2019 | Sep 30, 2019 | $26.06M | +51.6% |
| Q2 FY2019 | Jun 30, 2019 | $22.14M | +91.4% |
| Q1 FY2019 | Mar 31, 2019 | $12.67M | – |
| Q4 FY2018 | Dec 31, 2018 | $17.19M | – |
| Q3 FY2018 | Sep 30, 2018 | $17.19M | – |
| Q2 FY2018 | Jun 30, 2018 | $11.57M | – |
See a number that looks wrong?